Ocriplasmin for vitreoretinal diseases.
Article Details
- CitationCopy to clipboard
Tsui I, Pan CK, Rahimy E, Schwartz SD
Ocriplasmin for vitreoretinal diseases.
J Biomed Biotechnol. 2012;2012:354979. doi: 10.1155/2012/354979. Epub 2012 Oct 14.
- PubMed ID
- 23193358 [ View in PubMed]
- Abstract
Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Ocriplasmin Fibronectin Protein Humans YesCleavageDetails